Key Highlights of the Report:

Ø Growing Demand in Chronic Pain Management: The increasing prevalence of chronic pain conditions, particularly among the aging population, is driving the demand for Oxycodone.

Ø Regulatory and Safety Advancements: The development of abuse-deterrent formulations and stringent regulatory frameworks are enhancing the safe use of Oxycodone.

Ø Opportunities in Emerging Markets: Untapped markets in developing regions present significant growth opportunities for Oxycodone manufacturers.

Ø Integration of Digital Health Tools: The rise of telemedicine and digital health tools is improving pain management practices, potentially increasing Oxycodone prescriptions.

Ø Challenges from the Opioid Crisis: Ongoing concerns about opioid misuse and addiction continue to pose significant challenges, influencing market dynamics and regulatory policies.

According to a new report by UnivDatos, the Oxycodone Market is registered a value of USD 5.4 Billion in 2023 and would grow at a CAGR of ~5.13%. This can be attributed to the rising geriatric population coupled with the incidence of such chronic pain conditions as arthritis and back pain, and, therefore, the need for Opioid pain relievers like oxycodone also rises. The National Institutes of Health (NIH) (.gov) stated in the report that in 2023, new chronic pain cases were high, at 52.4 cases per 1,000 persons per year. This is compared to other common chronic conditions, such as diabetes (7.1 cases/1,000 per year), depression (15.9 cases/ 1,000 per year), and hypertension (45.3 cases/1,000 per year). Additionally, the growing demand for oxycodone has led to increased revenue for pharmaceutical companies producing and selling this medication.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/oxycodone-market?popup=report-enquiry

The ability to tailor treatments to individual needs and desired outcomes enhances patient satisfaction and drives market demand. Some of the most performed oxycodone include:

 On March 29, 2023, The U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose.

On June 21, 2022, Purdue Pharma L.P. announced that Nalmefene Hydrochloride injection, 2mg/2mL (1mg/1mL) is now available in the U.S. for use by healthcare professionals. In February 2022, FDA approved Purdue’s abbreviated new drug application (ANDA) for nalmefene hydrochloride injection for the treatment of known or suspected opioid overdose with natural or synthetic opioids.

According to the report, the impact of oxycodone resources has been identified to be high for the North American area. Some of how this impact has been felt include: Some of how this impact has been felt include:

The North American market dominated the oxycodone market in 2023 because of the well-developed healthcare sector coupled with high incidences of chronic pain. The growing occupancy of the aged in North America remains a factor in the rising incidences of chronic pain-associated conditions, including arthritis and neuropathic pain, and, thus, a rising need for strong opioids like oxycodone. The FDA and other regulatory organizations are also very influential in North America, and they have specific responsibilities of supervising and approving the oxycodone products in the market. For instance, in March 2022, following its assessment, the FDA thus concluded that the reformulated OxyContin has abuse resistance characteristics and therefore approved the new labeling, which states that the product has physical and chemical attributes that are supposed to render it difficult for injection and less suitable for intranasal abuse. Further, there are significant changes in its approach to pain management systems and new formulations of opioids that minimize the chance of addiction.

Click here to view the Report Description & TOC : https://univdatos.com/reports/oxycodone-market

Conclusion

In conclusion, oxycodone is still one of the most effective pain relievers in dealing with severe pain despite the problems posed by its vulnerability to misuse and dependence. Due to the ease of access to the drug, it is also a component of comprehensive treatment plans for patients suffering from chronic or debilitating pain conditions. However, the opioid crisis indicated the need for the reform of the legal system as well as a comprehensive healthcare framework to ensure compliance with best practices in prescribing opioids, preventing diversion as well as supporting affected individuals.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2024−2032.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis by Type, Application, Distribution channel, and Region

Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/